UBS initiates coverage on Jade Biosciences with Buy rating
UBS analyst Michael Yee has initiated coverage on Jade Biosciences with a Buy rating and a price target of $45.
*this image is generated using AI for illustrative purposes only.
UBS analyst Michael Yee has initiated coverage on Jade Biosciences with a Buy rating and a price target of $45. The rating reflects a positive outlook on the company's stock performance.
Analyst Details
The coverage was initiated by Michael Yee, an analyst at UBS. The firm set a price target of $45 for Jade Biosciences.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| UBS | Michael Yee | Buy | $45 |
What key factors could drive Jade Biosciences' stock to meet or exceed the $45 price target?
How might Jade Biosciences' upcoming clinical trial results influence investor sentiment?
What competitive advantages does Jade Biosciences have over its peers in the biotech sector?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
